Research Alliance Corporation III Class A Ordinary Shares
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $94.7M
- Price
- $24.60
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.45%
- Volume
- 4.7K
About
Research Alliance Corporation III functions as a blank check company, also referred to as a Special Purpose Acquisition Company (SPAC). Its primary objective is to complete a business combination, which might take the form of a merger, an equity exchange, an acquisition of assets or stock, or a corporate reorganization, with one or more other companies. The firm was established on February 19, 2026, and its main offices are located in New York, NY.
Quick stats
Shares outstanding9.1M
Computed float7.5M
Float / shares82.4%
Key info
SectorFinancial Services
IndustryShell Companies
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002118032
AI Summary
AI-generated27d agomajorbullishm and a
Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome
RACC has entered into a definitive business combination agreement with Oak Hill Bio to create a publicly listed company focused on the Phase 3 antisense therapy rugonersen for Angelman syndrome.
The transaction is expected to provide approximately $175 million in gross proceeds, consisting of $75 million from RACC’s fully backstopped trust and a $100 million PIPE priced at $10.00 per share.
The combined company is expected to close by year-end 2026 and trade on Nasdaq under the ticker symbol "OAKH", with Oak Hill CEO Josh Distler leading the new entity.
Red flags
- Phase 3 data readout not expected until 2H2029, implying long cash burn runway before potential commercialization